Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D	C. 20549
---------------	----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIF

OMB APP	ROVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  HAASER CHARLES B					2. Issuer Name and Ticker or Trading Symbol YIELD10 BIOSCIENCE, INC. [ YTEN ]										ationship of Reporting k all applicable) Director Officer (give title		10% Ow Other (sp		/ner	
(Last) (First) (Middle) C/O YIELD10 BIOSCIENCE, INC. 19 PRESIDENTIAL WAY					3. Date of Earliest Transaction (Month/Day/Year) 02/11/2021										below) below) VP Fin & Chief Accting Officer				cer	
(Street) WOBUR (City)			1801 Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indi Line) X	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date			2. Transac Date (Month/Da	Day/Year) if a		2A. Deemed Execution Date, f any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Secu Bene Owne		cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) (D)	or Pri	ce	Reported Transaction(s (Instr. 3 and 4				(Instr. 4)		
Common Stock 02/11.				02/11/2	021			F		693(1)	D	\$2	22.77 2,77		775		D			
Common Stock														3,306 <sup>(2)</sup>			I	By 401(k) Plan		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Gecurity or Exercise (Month/Day/Year) if any					Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exerc ion Da /Day/Y		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares							

## **Explanation of Responses:**

- 1. Represents shares withheld in payment of withholding taxes upon vesting of RSUs granted 2/11/20.
- 2. Shares acquired as Company matching contributions under the Yield10 Bioscience, Inc. 401(k) Plan.

/s/ Megan N. Gates, attorney-

in-fact

\*\* Signature of Reporting Person Date

02/16/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.